Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TCT In Brief

This article was originally published in The Gray Sheet

Executive Summary

HORIZONS-AMI: Two-year follow-up results from the 3,000-patient randomized trial show that ischemia-driven target lesion revascularization - the primary endpoint of the study - was 6.8% in patients receiving Boston Scientific's Taxus Express stent compared to 11.6% for those treated with a bare metal stent, firm reports during the Transcatheter Cardiovascular Therapeutics conference in San Francisco. For the secondary endpoint, target vessel revascularization, the rates for the Taxus Express and bare metal stent groups were 8.9% and 13.3%, respectively. The rate of major adverse cardiac events at two years was 11% for the drug-eluting stent and 11.2% for the bare metal stent. HORIZONS-AMI is designed to assess the safety and efficacy of Taxus Express in high-risk acute myocardial infarction patients

You may also be interested in...

Abiomed Markets Impella 2.5 Cardiac Assist Device To Cath Labs

Abiomed is targeting its Impella 2.5 cardiac assist device at the top 300 interventional cardiology labs in the United States, firm CEO Michael Minogue said in a June 2 conference call announcing the market launch

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts